SEC Form 4 · accession 0001179110-16-019347
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James A Schoeneck
Officer — President and CEO · Director
Period of report
Feb 11, 2016
Accepted (ET)
Feb 16, 2016 · 6:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Feb 11, 2016 | A | 147,000 | A | — | — | Common Stock | 147,000 | 147,000 | D |
| Stock OptionF3 | $16.07 | Feb 11, 2016 | A | 361,000 | A | — | Feb 11, 2026 | Common Stock | 361,000 | 361,000 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
- F2These restricted stock units are scheduled to vest 25% on December 1, 2016, 25% on December 1, 2017, 25% on December 1, 2018, and 25% on December 1, 2019, assuming continued employment through the applicable vesting date.
- F3These stock options are exercisable in 48 equal monthly installments.